| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO22 |
| Uniprot No | Q8NEZ5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-403aa |
| 氨基酸序列 | MEPVGCCGEC RGSSVDPRST FVLSNLAEVV ERVLTFLPAK ALLRVACVCR LWRECVRRVL RTHRSVTWIS AGLAEAGHLE GHCLVRVVAE ELENVRILPH TVLYMADSET FISLEECRGH KRARKRTSME TALALEKLFP KQCQVLGIVT PGIVVTPMGS GSNRPQEIEI GESGFALLFP QIEGIKIQPF HFIKDPKNLT LERHQLTEVG LLDNPELRVV LVFGYNCCKV GASNYLQQVV STFSDMNIIL AGGQVDNLSS LTSEKNPLDI DASGVVGLSF SGHRIQSATV LLNEDVSDEK TAEAAMQRLK AANIPEHNTI GFMFACVGRG FQYYRAKGNV EADAFRKFFP SVPLFGFFGN GEIGCDRIVT GNFILRKCNE VKDDDLFHSY TTIMALIHLG SSK |
| 分子量 | 44.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FBXO22蛋白的3篇参考文献示例(注意：文献为虚拟概括，具体请核实真实数据库)：
1. **文献名称**：*FBXO22 regulates p53 ubiquitination and degradation in human cancers*
**作者**：Zhu H, et al.
**摘要**：研究揭示了FBXO22作为SCF泛素连接酶复合物的底物识别亚基，通过介导p53蛋白的泛素化修饰促进其降解，进而影响肿瘤细胞的增殖和凋亡。文中利用重组人FBXO22蛋白验证其与p53的相互作用。
2. **文献名称**：*Structural and functional analysis of FBXO22 in DNA damage response*
**作者**：Xu Y, et al.
**摘要**：通过体外表达重组人FBXO22蛋白，结合晶体结构解析，阐明了其在DNA损伤应答中的功能，表明FBXO22通过泛素化修饰修复蛋白调控基因组稳定性。
3. **文献名称**：*FBXO22 suppresses metastasis in breast cancer by targeting SNAIL for degradation*
**作者**：Liang Q, et al.
**摘要**：研究发现FBXO22通过识别并降解转录因子SNAIL，抑制上皮间质转化(EMT)。实验利用重组FBXO22蛋白验证了其对SNAIL的泛素化活性，为乳腺癌治疗提供潜在靶点。
4. **文献名称**：*Recombinant FBXO22 protein modulates α-synuclein aggregation in Parkinson's disease models*
**作者**：Chen L, et al.
**摘要**：本研究通过纯化重组人FBXO22蛋白，证实其与α-synuclein相互作用，减少异常聚集，可能为神经退行性疾病提供新的干预策略。
(注：以上文献为示例性质，具体研究需参考真实发表的论文。)
**Background of Recombinant Human FBXO22 Protein**
The recombinant human FBXO22 protein is a crucial member of the F-box protein family, which functions as a substrate-recognition component of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex. FBXO22 contains an F-box domain that facilitates interaction with Skp1. enabling the complex to target specific proteins for ubiquitination and subsequent degradation via the proteasome. This protein plays diverse roles in cellular processes, including cell cycle regulation, DNA damage response, apoptosis, and epithelial-mesenchymal transition (EMT).
Emerging studies highlight FBXO22’s dual role in cancer biology. It acts as a tumor suppressor by promoting the degradation of oncogenic substrates (e.g., NOTCH2. EMT-related proteins) but can also exhibit oncogenic activity by destabilizing tumor suppressors like p53 under certain conditions. Dysregulation of FBXO22 is linked to tumor progression, metastasis, and drug resistance in cancers such as breast, liver, and lung carcinomas.
Recombinant FBXO22 protein, typically expressed in *E. coli* or mammalian systems, is widely used in biochemical assays, protein interaction studies, and functional analyses to unravel its substrate specificity, regulatory mechanisms, and disease-associated mutations. Its structural and functional characterization provides insights into SCF complex dynamics and potential therapeutic strategies targeting ubiquitination pathways. Research on FBXO22 continues to explore its broader implications in cellular homeostasis and cancer, emphasizing its value as a biomarker or therapeutic target.
×
